A Closer Look at Airvo
Nasal high-flow therapy is relatively new to respiratory care, and it’s now finding its way into the home. Fisher and Paykel’s James Gibbons explains how it works.
- By David Kopf
- Oct 24, 2018
As the respiratory care field learns more about its patients and their conditions, it’s discovering that there are a variety of patients having issues with secretion mobilization. Essentially, they need help clearing their upper respiratory system so that they can achieve strong, deep, even breaths.
Enter nasal high-flow therapy, which delivers warm, humid air at continuous pressure to liquefy debris in the upper airway and help patients cough that material out. The therapy debuted in the hospital setting, but now new products, such as Airvo from Fisher & Paykel Healthcare Inc., are bringing the therapy into the home setting.
At last week’s Medtrade, I met with James Gibbons, Airvo product manager for Fisher & Paykel, to learn more about nasal high-flow therapy and how Airvo works for HME patients:
David Kopf is the Executive Editor of HME Business and DME Pharmacy magazine. Follow him on Twitter at @postacutenews.